Registry study for heart PYP scans in possible ATTR amyloidosis
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study collects information from adults who have been diagnosed with, or are being checked for, ATTR amyloidosis (a condition where abnormal protein builds up in the body) using a heart PYP scan. Your participation may help doctors better understand how these scans relate to diagnosis and follow-up over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 20 years old
- You have a confirmed diagnosis or are being ruled out for ATTR amyloidosis
- You cannot be pregnant or breastfeeding
- You should not have serious other illnesses that are expected to limit life to under 6 months
- You must agree to clinical follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how often a specific heart condition (ATTR amyloid) occurs in people age 65+ who have HFpEF. It also tries to predict who might have it, using a special heart scan, and may help your care team identify it earlier.
This study looks at past bone scans to find signs of a heart condition called amyloidosis, where abnormal proteins build up in the heart. It may help identify more people with this condition and improve future diagnosis.
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
This research study checks a small sample of heart tissue during pacemaker or defibrillator placement to see if amyloidosis, a condition where abnormal proteins build up in organs, is present. It aims to find amyloidosis earlier so treatment can start sooner.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.